IL-17A: A Major Cytokine of the IL-17 Family, a Key Inflammation Target in Skin Diseases, or Inflammation-Associated Cancers!

IL-17A: A Major Cytokine of the IL-17 Family, a Key Inflammation Target in Skin Diseases, or Inflammation-Associated Cancers!

Interleukin-17A (IL17A, commonly referred to as IL-17), is a cytokine that belongs to the interleukin 17 family. The IL-17 family comprises at least six members (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F). IL-17 ligands exert their biological effects by binding to the corresponding heterodimeric receptors (IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE). Among all the members, IL-17A is best understood. Accumulating research suggested that IL-17A plays a central role in inflammatory processes and participates in cancer progression (Click to Read More about IL-17A).

On March 25, 202, China has achieved a significant milestone by successfully launching the first developed monoclonal antibody drug targeting IL-17A (Xeligekimab, GR1501). GR1501 is a human IL-17A-neutralizing IgG4 monoclonal antibody, which was applied for the treatment in skin and rheumatic diseases like psoriasis, spondylitis, even inflammation-associated cancers. In recent years, IL-17A’s exceptional clinical efficacy made it a highly sought-after inflammation target globally (IL-17A Clinical Trials for Drug Development).

To fully support researchers and pharmaceutical companies in their research on IL-17A in psoriasis, autoimmune diseases, or cancers, CUSABIO presents a series of IL-17A active proteins to support your research on the mechanism of IL-17A or its potential clinical value. (click for the full list of IL-17A products: IL-17A Proteins; IL-17A antibodies; IL-17A ELISAs)